Therapeutic application of chimeric RNA/DNA oligonucleotide based gene therapy

Li-Wen Lai, Yeong Hau H Lien

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Chimeric RNA/DNA oligonucleotides, or chimera, have emerged as a breakthrough technology for treating genetic disorders. Chimera have been shown to induce correction of point mutations in several genetic disease models without utilising the viral vectors. Recent studies of chimera-based gene therapy in genetic disease models are reviewed. Chimera were delivered intravenously, intramuscularly, intradermally, or topically with or without vehicles. Correction of the mutation at genotypic and phenotypic levels was assessed using various methods. The gene correction frequency varied, ranging from 1 - 40%. The resulting phenotype changes lasted longer than one year in some studies. The most dramatic phenotypic change is the reduction of serum bilirubin level by 50% in the Gunn rat, a model for Crigler-Najjar syndrome. Chimera based gene therapy has the potential to develop into powerful therapeutic modality for genetic diseases. 2001

Original languageEnglish (US)
Pages (from-to)41-47
Number of pages7
JournalExpert Opinion on Biological Therapy
Volume1
Issue number1
StatePublished - 2001

Fingerprint

Gene therapy
Inborn Genetic Diseases
Oligonucleotides
Genetic Therapy
RNA
DNA
Genetic Models
Bilirubin
Crigler-Najjar Syndrome
Gunn Rats
Rats
Therapeutics
Genes
Point Mutation
Gene Frequency
Technology
Phenotype
Mutation
Serum

Keywords

  • Carbonic anhydrase ii
  • Crigler-najjar syndrome type I
  • Dnchenne muscular dystrophy
  • Dystrophin
  • Fabry disease. Factor ix
  • Genetic disease
  • Homologous pairing
  • Mismatch repair
  • Tyrosinase
  • Udp-glucuronosyl-transferase

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Genetics
  • Immunology

Cite this

Therapeutic application of chimeric RNA/DNA oligonucleotide based gene therapy. / Lai, Li-Wen; Lien, Yeong Hau H.

In: Expert Opinion on Biological Therapy, Vol. 1, No. 1, 2001, p. 41-47.

Research output: Contribution to journalArticle

@article{e5a68a3f43134f3db654c542ca82039f,
title = "Therapeutic application of chimeric RNA/DNA oligonucleotide based gene therapy",
abstract = "Chimeric RNA/DNA oligonucleotides, or chimera, have emerged as a breakthrough technology for treating genetic disorders. Chimera have been shown to induce correction of point mutations in several genetic disease models without utilising the viral vectors. Recent studies of chimera-based gene therapy in genetic disease models are reviewed. Chimera were delivered intravenously, intramuscularly, intradermally, or topically with or without vehicles. Correction of the mutation at genotypic and phenotypic levels was assessed using various methods. The gene correction frequency varied, ranging from 1 - 40{\%}. The resulting phenotype changes lasted longer than one year in some studies. The most dramatic phenotypic change is the reduction of serum bilirubin level by 50{\%} in the Gunn rat, a model for Crigler-Najjar syndrome. Chimera based gene therapy has the potential to develop into powerful therapeutic modality for genetic diseases. 2001",
keywords = "Carbonic anhydrase ii, Crigler-najjar syndrome type I, Dnchenne muscular dystrophy, Dystrophin, Fabry disease. Factor ix, Genetic disease, Homologous pairing, Mismatch repair, Tyrosinase, Udp-glucuronosyl-transferase",
author = "Li-Wen Lai and Lien, {Yeong Hau H}",
year = "2001",
language = "English (US)",
volume = "1",
pages = "41--47",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Therapeutic application of chimeric RNA/DNA oligonucleotide based gene therapy

AU - Lai, Li-Wen

AU - Lien, Yeong Hau H

PY - 2001

Y1 - 2001

N2 - Chimeric RNA/DNA oligonucleotides, or chimera, have emerged as a breakthrough technology for treating genetic disorders. Chimera have been shown to induce correction of point mutations in several genetic disease models without utilising the viral vectors. Recent studies of chimera-based gene therapy in genetic disease models are reviewed. Chimera were delivered intravenously, intramuscularly, intradermally, or topically with or without vehicles. Correction of the mutation at genotypic and phenotypic levels was assessed using various methods. The gene correction frequency varied, ranging from 1 - 40%. The resulting phenotype changes lasted longer than one year in some studies. The most dramatic phenotypic change is the reduction of serum bilirubin level by 50% in the Gunn rat, a model for Crigler-Najjar syndrome. Chimera based gene therapy has the potential to develop into powerful therapeutic modality for genetic diseases. 2001

AB - Chimeric RNA/DNA oligonucleotides, or chimera, have emerged as a breakthrough technology for treating genetic disorders. Chimera have been shown to induce correction of point mutations in several genetic disease models without utilising the viral vectors. Recent studies of chimera-based gene therapy in genetic disease models are reviewed. Chimera were delivered intravenously, intramuscularly, intradermally, or topically with or without vehicles. Correction of the mutation at genotypic and phenotypic levels was assessed using various methods. The gene correction frequency varied, ranging from 1 - 40%. The resulting phenotype changes lasted longer than one year in some studies. The most dramatic phenotypic change is the reduction of serum bilirubin level by 50% in the Gunn rat, a model for Crigler-Najjar syndrome. Chimera based gene therapy has the potential to develop into powerful therapeutic modality for genetic diseases. 2001

KW - Carbonic anhydrase ii

KW - Crigler-najjar syndrome type I

KW - Dnchenne muscular dystrophy

KW - Dystrophin

KW - Fabry disease. Factor ix

KW - Genetic disease

KW - Homologous pairing

KW - Mismatch repair

KW - Tyrosinase

KW - Udp-glucuronosyl-transferase

UR - http://www.scopus.com/inward/record.url?scp=0035225675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035225675&partnerID=8YFLogxK

M3 - Article

C2 - 11727546

AN - SCOPUS:0035225675

VL - 1

SP - 41

EP - 47

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 1

ER -